IRIS

Sfoglia per Titolo

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 4.725 a 4.744 di 43.414
Titolo Data di pubblicazione Autore(i) File
Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives 1-gen-2003 Vicenzi, E; Gatti, A; Ghezzi, S; Oreste, P; Zoppetti, G; Poli, Guido
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 1-gen-2012 Clementi, Nicola; Criscuolo, Elena; Castelli, Matteo; Clementi, Massimo
Broadly neutralizing anti-influenza human monoclonal antibodies and their possible role in predictive medicine 1-gen-2013 Castelli, M.; Clementi, Nicola; Mancini, Nicasio; Clementi, Massimo; Burioni, R.
Broadly neutralizing human monoclonal antibodies: a novel resource against influenza viruses 1-gen-2013 Criscuolo, E; Cappelletti, F; Clementi, N; Mancini, N; Sautto, Ga; Diotti, Ra; Clementi, M and Burioni R
Broca's Area and Lexical-Semantic Processing 1-gen-2009 Cappa, STEFANO FRANCESCO; Perani, DANIELA FELICITA L.
Broca’s Area as a Pre-articulatory Phonetic Encoder: Gating the Motor Program 1-gen-2018 Ferpozzi, Valentina; Fornia, Luca; Montagna, Marcella; Siodambro, Chiara; Castellano, Antonella; Borroni, Paola; Riva, Marco; Rossi, Marco; Pessina, Federico; Bello, Lorenzo; Cerri, Gabriella
Broken affordances, broken objects: a TMS study 1-gen-2009 Buccino, G; Sato, M; Cattaneo, L; Roda', F; Riggio, L
Broken heart syndrome: tako-tsubo cardiomyopathy 1-gen-2009 Latib, Azeem; Ielasi, Alfonso; Montorfano, M; Colombo, Antonio
Brolucizimab—leading an era of structural revolution for long-term VEGF suppression 1-gen-2019 Sharma, Ashish; Kumar, Nilesh; Kuppermann, Baruch D.; Bandello, Francesco
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials 1-gen-2022 Singer, M.; Khanani, A. M.; Wolf, A.; Flores, R.; Chhablani, J.; B, G. B.; Clemens, A.; Gedif, K.; Liu, X.; Mulyukov, Z.; Querques, G.
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD) 1-gen-2020 Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Sharma, Rohini; Bandello, Francesco; Kuppermann, Baruch D.; Regillo, Carl D.
Brolucizumab and immunogenicity 1-gen-2020 Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Sharma, Rohini; Bandello, Francesco; Kuppermann, Baruch D.; Loewenstein, Anat
Brolucizumab in polypoidal choroidal vasculopathy 1-gen-2022 Sharma, Ashish; Parachuri, Nikulaa; Kumar, Nilesh; Kuppermann, Baruch D; Loewenstein, Anat; Bandello, Francesco
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk 1-gen-2022 Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Sahyoun, Jean-Yves; Kuppermann, Baruch D; Bandello, Francesco
Brolucizumab-foreseeable workflow in the current scenario 1-gen-2021 Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Kuppermann, Baruch D; Bandello, Francesco; Regillo, Carl D; Boyer, David; Nguyen, Quan Dong
Brolucizumab-key learnings from HAWK and HARRIER 1-gen-2020 Sharma, Ashish; Parachuri, Nikulaa; Kumar, Nilesh; Sharma, Rohini; Bandello, Francesco; Kuppermann, Baruch D.; Loewenstein, Anat
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world 1-gen-2020 Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Singh, Sonali; Bandello, Francesco; Kuppermann, Baruch D.; Loewenstein, Anat
Brolucizumab: is extended VEGF suppression on the horizon? 1-gen-2019 Sharma, Ashish; Kumar, Nilesh; Kuppermann, Baruch D; Loewenstein, Anat; Bandello, Francesco
Brolucizumab: the road ahead 1-gen-2020 Sharma, Ashish; Kumar, Nilesh; Bandello, Francesco; Kuppermann, Baruch D; Loewenstein, Anat; Regillo, Carl D
Brolucizumab—another anti-VEGF or beyond 1-gen-2020 Sharma, Ashish; Parachuri, Nikulaa; Kumar, Nilesh; Sharma, Rohini; Bandello, Francesco; Kuppermann, Baruch D.; Loewenstein, Anat
Mostrati risultati da 4.725 a 4.744 di 43.414
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile